Teixeira L R, Vargas F S, Carmo A O, Silva L M, Marchi E, Light R W
Instituto do Coracao, Faculty of Medicine, University of São Paulo, Brazil; Department of Medicine, University of Săo Paulo, Brazil.
Respiration. 1998;65(4):304-8. doi: 10.1159/000029281.
The ideal pleural sclerosing agent should be easily administered, without significant side effects, inexpensive, and widely available. None of the agents presently used meets all of these criteria. Ethanolamine oleate (ETH) is a sclerosing agent used in the sclerotherapy treatment of varicose veins of the legs and esophagus. The objective of the present study was to assess the efficacy of ETH as a pleural sclerosant in rabbits. An additional objective was to assess if better results were obtained when dextrose 50% (D50) as opposed to saline was used as the diluent. Each group of 10 rabbits received a total volume of 2 ml intrapleurally. The eight treatments were as follows: (1) 2 ml saline; (2) 2 ml D50; (3) 25 mg ETH plus 1.5 ml saline; (4) 25 mg ETH plus 1.5 ml D50; (5) 50 mg ETH plus 1.0 ml saline; (6) 50 mg ETH plus 1 ml D50; (7) 75 mg ETH plus 0.5 ml D50, and (8) 100 mg ETH. The rabbits were sacrificed 28 days after the injection. The intrapleural instillation of ETH resulted in evident pleurodesis, which was dose-dependent; 100 mg ETH induced significantly (p<0.05) more adhesions than did any other treatment. The selection of the diluent had no effect on the pleurodesis. The microscopic examination of the right visceral pleura showed that the mean degree of fibrosis after 100 mg ETH was significantly (p<0.05) greater than that after the other solutions. The mean degree of pleural inflammation, lung inflammation and lung fibrosis was minimal in all the groups. From this study we conclude that undiluted ETH produces pleurodesis in our experimental model. At the doses used, the pleurodesis was less than that produced after talc, tetracycline derivatives or silver nitrate in the same model.
理想的胸膜硬化剂应易于给药、无明显副作用、价格低廉且易于获得。目前使用的任何一种药物都不能满足所有这些标准。油酸乙醇胺(ETH)是一种用于腿部和食管静脉曲张硬化治疗的硬化剂。本研究的目的是评估ETH作为兔胸膜硬化剂的疗效。另一个目的是评估与生理盐水相比,使用50%葡萄糖(D50)作为稀释剂是否能获得更好的效果。每组10只兔子经胸膜内给予总量为2 ml的药物。八种处理如下:(1)2 ml生理盐水;(2)2 ml D50;(3)25 mg ETH加1.5 ml生理盐水;(4)25 mg ETH加1.5 ml D50;(5)50 mg ETH加1.0 ml生理盐水;(6)50 mg ETH加1 ml D50;(7)75 mg ETH加0.5 ml D50;(8)100 mg ETH。注射后28天处死兔子。胸膜内注入ETH导致明显的胸膜固定,且呈剂量依赖性;100 mg ETH诱导的粘连明显(p<0.05)多于其他任何处理。稀释剂的选择对胸膜固定没有影响。右侧脏胸膜的显微镜检查显示,100 mg ETH后的平均纤维化程度明显(p<0.05)高于其他溶液后的程度。所有组的胸膜炎症、肺部炎症和肺纤维化的平均程度均最小。从本研究中我们得出结论,在我们的实验模型中,未稀释的ETH可产生胸膜固定。在所使用的剂量下,胸膜固定程度低于同一模型中滑石粉、四环素衍生物或硝酸银后的程度。